Beate Sander Bio

Beate Sander

RN, MBA, MEcDev, PhD

 

Dr. Beate Sander is a Scientist and Director of Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative), University Health Network. She is an Associate Professor and Faculty Lead, Health Technology Assessment program, Institute of Health Policy, Management and Evaluation at the University of Toronto. She also holds appointments as Adjunct Scientist at Public Health Ontario and the Institute for Clinical Evaluative Sciences (ICES). Dr. Sander is a member of Canada’s National Advisory Committee on Immunization (NACI) and the incoming Vice President of the Society of Medical Decision Making.

Dr. Sander earned her Bachelors of Nursing Science from the Chemnitz School of Nursing in Germany, a Master’s of Business Administration from the Technische Universitat Bergakademie Freiberg, a Master’s of Economics of Development from the Australian National University and a PhD in Health Services Research from the University of Toronto.

 

Dr. Sander’s areas of expertise include health economics, decision analysis and simulation, infectious disease epidemiology and population health decision-making. Her current research focuses on economic evaluation, ranging from methods development to applied research on infectious diseases. She has spearheaded the linkage of laboratory and reportable disease data with administrative data, enabling novel approaches to study the burden of infectious diseases. Recent work on Lyme disease include systematic reviews on health outcomes, quality of life and economic evaluations for Lyme disease as well as a costing study, determining healthcare resource utilization attributable to Lyme disease.

 

Dr. Sander is a Principal Applicant on the grant and will act as the Network’s Scientific Co-Director. She will direct the health services research theme (Pillar 3), including determining long-term outcomes and burden of disease, and conducting economic evaluation. She will also have involvement in risk reduction and prevention activities (Pillar 2) and patient and community engagement strategy (Pillar 4).